{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:20:46Z","timestamp":1794918046538,"version":"4.9.1"},"reference-count":231,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advances in immunotherapy have transformed the therapeutic landscape of gynecological cancers; however, durable responses remain limited by tumor heterogeneity and immune evasion mechanisms. Emerging evidence highlights epigenetic modifications comprising of DNA methylation, histone modifications, and RNA methylation as pivotal regulators of the tumor immune microenvironment and immunotherapy efficacy. This review comprehensively explores how these epigenetic alterations modulate immune cell infiltration, antigen presentation, immune checkpoint expression, and tumor immunogenicity across cervical, ovarian, and endometrial cancers. We also delineate the impact of specific epigenetic enzymes, such as DNMTs, HDACs, BET and RNA methyltransferases, in shaping immune responses and discuss the therapeutic potential of targeting these regulators to sensitize tumors to immune checkpoint inhibitors, cancer vaccines, cytokine based treatments and adoptive T-cell therapies. Furthermore, we examine the integration of epigenetic agents such as DNMT and HDAC inhibitors with immunotherapies in preclinical and clinical settings, emphasizing their synergistic capacity to overcome immunoresistance. By illuminating the interplay between epigenetic regulation and immune dynamics, this review underscores a paradigm shift toward precision immunoepigenetic strategies, offering a promising framework for enhancing therapeutic outcomes in gynecological malignancies.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s13046-025-03509-1","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:42:12Z","timestamp":1759236132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies"],"prefix":"10.1186","volume":"44","author":[{"given":"Chenyuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"3509_CR1","doi-asserted-by":"publisher","unstructured":"Priyadarshini S, Swain PK, Agarwal K, Jena D, Padhee S. Trends in gynecological cancer incidence, mortality, and survival among elderly women: A SEER study. AGING Med 2024;7:179\u201388. https:\/\/doi.org\/10.1002\/agm2.12297.","DOI":"10.1002\/agm2.12297"},{"key":"3509_CR2","doi-asserted-by":"publisher","unstructured":"Fabbro M, Colombo P-E, Leaha CM, Rouanet P, Carr\u00e8re S, Quenet F, et al. Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers (Basel) 2020;12. https:\/\/doi.org\/10.3390\/cancers12082184.","DOI":"10.3390\/cancers12082184"},{"key":"3509_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10555-023-10113-2","volume":"42","author":"C Zhang","year":"2023","unstructured":"Zhang C, Sheng Y, Sun X, Wang Y. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions. Cancer Metastasis Rev. 2023;42:891\u2013925. https:\/\/doi.org\/10.1007\/s10555-023-10113-2.","journal-title":"Cancer Metastasis Rev"},{"key":"3509_CR4","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3509_CR5","doi-asserted-by":"publisher","unstructured":"S TK. Cervical Cancer. N Engl J Med 2025;392:56\u201371. https:\/\/doi.org\/10.1056\/NEJMra2404457.","DOI":"10.1056\/NEJMra2404457"},{"key":"3509_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"3509_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13148-024-01740-9","volume":"16","author":"T Dang","year":"2024","unstructured":"Dang T, Guan X, Cui L, Ruan Y, Chen Z, Zou H, et al. Epigenetics and immunotherapy in colorectal cancer: progress and promise. Clin Epigenetics. 2024;16:123. https:\/\/doi.org\/10.1186\/s13148-024-01740-9.","journal-title":"Clin Epigenetics"},{"key":"3509_CR8","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1039\/c6tx00047a","volume":"5","author":"H Chang","year":"2016","unstructured":"Chang H, Wang D, Xia W, Pan X, Huo W, Xu S, et al. Epigenetic disruption and glucose homeostasis changes following low-dose maternal bisphenol A exposure. Toxicol Res (Camb). 2016;5:1400\u20139. https:\/\/doi.org\/10.1039\/c6tx00047a.","journal-title":"Toxicol Res (Camb)"},{"key":"3509_CR9","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.3892\/ol.2018.7726","volume":"15","author":"M Yano","year":"2018","unstructured":"Yano M, Yasuda M, Sakaki M, Nagata K, Fujino T, Arai E, et al. Association of histone deacetylase expression with histology and prognosis of ovarian cancer. Oncol Lett. 2018;15:3524\u201331. https:\/\/doi.org\/10.3892\/ol.2018.7726.","journal-title":"Oncol Lett"},{"key":"3509_CR10","doi-asserted-by":"publisher","unstructured":"Ramarao-Milne P, Kondrashova O, Barry S, Hooper JD, Lee JS, Waddell N. Histone Modifying Enzymes in Gynaecological Cancers. Cancers (Basel) 2021;13. https:\/\/doi.org\/10.3390\/cancers13040816.","DOI":"10.3390\/cancers13040816"},{"key":"3509_CR11","doi-asserted-by":"publisher","first-page":"9162","DOI":"10.7150\/thno.59605","volume":"11","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Yuan Y, Chen M, Li S, Bai J, Zhang Y, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression. Theranostics. 2021;11:9162\u201376. https:\/\/doi.org\/10.7150\/thno.59605.","journal-title":"Theranostics"},{"key":"3509_CR12","doi-asserted-by":"publisher","unstructured":"Chan S, Cheng A, La Thangue N, Kerr D. Epigenetic therapeutics to overcome resistance against immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC): a proof-of-concept clinical trial. Lancet Reg Heal \u2013 West Pacific 2025;55. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101425.","DOI":"10.1016\/j.lanwpc.2024.101425"},{"key":"3509_CR13","doi-asserted-by":"crossref","unstructured":"You L, Han Q, Zhu L, Zhu Y, Bao C, Yang C, et al. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells. Front Immunol 2020;11.","DOI":"10.3389\/fimmu.2020.01787"},{"key":"3509_CR14","doi-asserted-by":"crossref","unstructured":"Kartikasari AER, Prakash MD, Cox M, Wilson K, Boer JC, Cauchi JA, et al. Therapeutic Cancer Vaccines\u2014T Cell Responses and Epigenetic Modulation. Front Immunol 2019;9.","DOI":"10.3389\/fimmu.2018.03109"},{"key":"3509_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/cbin.10729","volume":"41","author":"E Cacan","year":"2017","unstructured":"Cacan E. Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells. Cell Biol Int. 2017;41:328\u201339. https:\/\/doi.org\/10.1002\/cbin.10729.","journal-title":"Cell Biol Int"},{"key":"3509_CR16","doi-asserted-by":"publisher","unstructured":"Yan M, Cao H, Tao K, Xiao B, Chu Y, Ma D, et al. HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers. Gene 2023;885:147704. https:\/\/doi.org\/10.1016\/j.gene.2023.147704.","DOI":"10.1016\/j.gene.2023.147704"},{"key":"3509_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-025-02255-4","volume":"24","author":"Y Ji","year":"2025","unstructured":"Ji Y, Xiao C, Fan T, Deng Z, Wang D, Cai W, et al. The epigenetic hallmarks of immune cells in cancer. Mol Cancer. 2025;24:66. https:\/\/doi.org\/10.1186\/s12943-025-02255-4.","journal-title":"Mol Cancer"},{"key":"3509_CR18","doi-asserted-by":"publisher","unstructured":"Kim DJ. The Role of the DNA Methyltransferase Family and the Therapeutic Potential of DNMT Inhibitors in Tumor Treatment. Curr Oncol 2025;32. https:\/\/doi.org\/10.3390\/curroncol32020088.","DOI":"10.3390\/curroncol32020088"},{"key":"3509_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/15592294.2015.1017198","volume":"10","author":"P Srivastava","year":"2015","unstructured":"Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Taverna P, et al. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10:237\u201346. https:\/\/doi.org\/10.1080\/15592294.2015.1017198.","journal-title":"Epigenetics"},{"key":"3509_CR20","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci. 2017;114:E10981\u201390. https:\/\/doi.org\/10.1073\/pnas.1712514114.","journal-title":"Proc Natl Acad Sci"},{"key":"3509_CR21","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1038\/s41598-020-60409-4","volume":"10","author":"S Moufarrij","year":"2020","unstructured":"Moufarrij S, Srivastava A, Gomez S, Hadley M, Palmer E, Austin PT, et al. Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer. Sci Rep. 2020;10:3470. https:\/\/doi.org\/10.1038\/s41598-020-60409-4.","journal-title":"Sci Rep"},{"key":"3509_CR22","doi-asserted-by":"publisher","unstructured":"Shi W-Y, Cao C, Liu L. Interferon \u03b1 Induces the Apoptosis of Cervical Cancer HeLa Cells by Activating both the Intrinsic Mitochondrial Pathway and Endoplasmic Reticulum Stress-Induced Pathway. Int J Mol Sci 2016;17. https:\/\/doi.org\/10.3390\/ijms17111832.","DOI":"10.3390\/ijms17111832"},{"key":"3509_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2217\/imt-2018-0158","volume":"11","author":"DS Green","year":"2019","unstructured":"Green DS, Husain SR, Johnson CL, Sato Y, Han J, Joshi B, et al. Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-\u03b1 and IFN-\u03b3 mediate antitumor effects in vitro and in a mouse model of human ovarian cancer. Immunotherapy. 2019;11:483\u201396. https:\/\/doi.org\/10.2217\/imt-2018-0158.","journal-title":"Immunotherapy"},{"key":"3509_CR24","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1054\/bjoc.1999.1053","volume":"82","author":"GH Windbichler","year":"2000","unstructured":"Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer. 2000;82:1138\u201344. https:\/\/doi.org\/10.1054\/bjoc.1999.1053.","journal-title":"Br J Cancer"},{"key":"3509_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/1078-0432.CCR-22-1893","volume":"29","author":"DS Green","year":"2023","unstructured":"Green DS, Ning F, Duemler A, Myers TG, Trewhitt K, Ekwede I, et al. Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial. Clin Cancer Res an Off J Am Assoc Cancer Res. 2023;29:349\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1893.","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"3509_CR26","doi-asserted-by":"publisher","unstructured":"Wang B, Zhu Y, Zhang Y, Ru Z, Chen L, Zhang M, et al. Hyperactivity of the IL-33-ILC2s-IL-13-M-MDSCs axis promotes cervical cancer progression. Int Immunopharmacol 2025;144:113693. https:\/\/doi.org\/10.1016\/j.intimp.2024.113693.","DOI":"10.1016\/j.intimp.2024.113693"},{"key":"3509_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fonc.2019.00682","volume":"9","author":"C Zhou","year":"2019","unstructured":"Zhou C, Tuong ZK, Frazer IH. Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System. Front Oncol. 2019;9:682. https:\/\/doi.org\/10.3389\/fonc.2019.00682.","journal-title":"Front Oncol"},{"key":"3509_CR28","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3892\/etm.2021.10726","volume":"22","author":"Y Bai","year":"2021","unstructured":"Bai Y, Li H, Lv R. Interleukin-17 activates JAK2\/STAT3, PI3K\/Akt and nuclear factor-\u03baB signaling pathway to promote the tumorigenesis of cervical cancer. Exp Ther Med. 2021;22:1291. https:\/\/doi.org\/10.3892\/etm.2021.10726.","journal-title":"Exp Ther Med"},{"key":"3509_CR29","doi-asserted-by":"publisher","unstructured":"Zeng X, Zhang Z, Gao Q-Q, Wang Y-Y, Yu X-Z, Zhou B, et al. Clinical Significance of Serum Interleukin-31 and Interleukin-33 Levels in Patients of Endometrial Cancer: A Case Control Study. Dis Markers 2016;2016:9262919. https:\/\/doi.org\/10.1155\/2016\/9262919.","DOI":"10.1155\/2016\/9262919"},{"key":"3509_CR30","doi-asserted-by":"publisher","unstructured":"Tanyi JL, Chiang CL-L, Chiffelle J, Thierry A-C, Baumgartener P, Huber F, et al. Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. Npj Vaccines 2021;6:36. https:\/\/doi.org\/10.1038\/s41541-021-00297-5.","DOI":"10.1038\/s41541-021-00297-5"},{"key":"3509_CR31","doi-asserted-by":"crossref","unstructured":"Koeneman BJ, Schreibelt G, Gorris MAJ, Hins - de Bree S, Westdorp H, Ottevanger PB, et al. Dendritic cell vaccination combined with carboplatin\/paclitaxel for metastatic endometrial cancer patients: results of a phase I\/II trial. Front Immunol 2024; 15.","DOI":"10.3389\/fimmu.2024.1368103"},{"key":"3509_CR32","doi-asserted-by":"publisher","unstructured":"Brown TA, Byrd K, Vreeland TJ, Clifton GT, Jackson DO, Hale DF, et al. Final analysis of a phase I\/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. Cancer Med 2019;8:4678\u201387. https:\/\/doi.org\/10.1002\/cam4.2378.","DOI":"10.1002\/cam4.2378"},{"key":"3509_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/1750743X.2025.2460964","volume":"17","author":"C Nasso","year":"2025","unstructured":"Nasso C, Silvia P, Sara Elena R, Veronica E, Francesca R, Ilaria C, et al. Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials. Immunotherapy. 2025;17:57\u201366. https:\/\/doi.org\/10.1080\/1750743X.2025.2460964.","journal-title":"Immunotherapy"},{"key":"3509_CR34","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00262-015-1712-6","volume":"64","author":"JT Mony","year":"2015","unstructured":"Mony JT, Zhang L, Ma T, Grabosch S, Tirodkar TS, Brozick J, et al. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunol Immunother. 2015;64:1095\u2013108. https:\/\/doi.org\/10.1007\/s00262-015-1712-6.","journal-title":"Cancer Immunol Immunother"},{"key":"3509_CR35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41392-023-01646-7","volume":"8","author":"Y Wang","year":"2023","unstructured":"Wang Y, Han J, Wang D, Cai M, Xu Y, Hu Y, et al. Anti-PD-1 antibody armored \u03b3\u03b4 T cells enhance anti-tumor efficacy in ovarian cancer. Signal Transduct Target Ther. 2023;8:399. https:\/\/doi.org\/10.1038\/s41392-023-01646-7.","journal-title":"Signal Transduct Target Ther"},{"key":"3509_CR36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s12094-024-03610-5","volume":"27","author":"X Jian","year":"2025","unstructured":"Jian X, Zhang J, Huang Y, Duan J, Linghu H, Li R. Early salvage therapy with anti-PD-1 antibody Camrelizumab in patients with advanced cervical cancer: a retrospective study. Clin Transl Oncol. 2025;27:693\u20138. https:\/\/doi.org\/10.1007\/s12094-024-03610-5.","journal-title":"Clin Transl Oncol"},{"key":"3509_CR37","doi-asserted-by":"publisher","first-page":"1454372","DOI":"10.3389\/fonc.2024.1454372","volume":"14","author":"J Yang","year":"2024","unstructured":"Yang J, Yu H, Zhang Y, Zhu M, Zhang M, Wang Q. Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis. Front Oncol. 2024;14:1454372. https:\/\/doi.org\/10.3389\/fonc.2024.1454372.","journal-title":"Front Oncol"},{"key":"3509_CR38","doi-asserted-by":"publisher","unstructured":"O\u2019Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and\/or metastatic cervical cancer. Gynecol Oncol 2021;163:274\u201380. https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.018.","DOI":"10.1016\/j.ygyno.2021.08.018"},{"key":"3509_CR39","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-22-1280","volume":"28","author":"J An","year":"2022","unstructured":"An J, Tang J, Li BX, Xiong H, Qiu H, Luo L, et al. Efficacy and Safety of the Anti\u2013PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study. Clin Cancer Res. 2022;28:5098\u2013106. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1280.","journal-title":"Clin Cancer Res"},{"key":"3509_CR40","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.2217\/fon-2021-0598","volume":"17","author":"A Oaknin","year":"2021","unstructured":"Oaknin A, Anna VT, Lucy G, Vanessa S, Cara M, Jubilee B, et al. Clinical Activity and Safety of the Anti-PD-1 Monoclonal Antibody Dostarlimab for Patients with Recurrent or Advanced dMMR Endometrial Cancer. Futur Oncol. 2021;17:3781\u20135. https:\/\/doi.org\/10.2217\/fon-2021-0598.","journal-title":"Futur Oncol"},{"key":"3509_CR41","doi-asserted-by":"publisher","unstructured":"Berton D, Pautier P, Lorusso D, Gennigens C, Gladieff L, Kryzhanivska A, et al. Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study. Gynecol Oncol 2024;186:191\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.025.","DOI":"10.1016\/j.ygyno.2024.05.025"},{"key":"3509_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2019.04.044","volume":"154","author":"A Oaknin","year":"2019","unstructured":"Oaknin A, Duska LR, Sullivan RJ, Pothuri B, Ellard SL, Leath CA III, et al. <strong>Preliminary safety, efficacy, and pharmacokinetic\/pharmacodynamic characterization from GARNET, a phase I\/II clinical trial of the anti\u2013PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial canc. Gynecol Oncol. 2019;154:17. https:\/\/doi.org\/10.1016\/j.ygyno.2019.04.044.","journal-title":"Gynecol Oncol"},{"key":"3509_CR43","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29:3044\u201360. https:\/\/doi.org\/10.3390\/curroncol29050247.","journal-title":"Curr Oncol"},{"key":"3509_CR44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/CCID.S24246","volume":"6","author":"G Tosti","year":"2013","unstructured":"Tosti G, Cocorocchio E, Pennacchioli E. Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol. 2013;6:245\u201356. https:\/\/doi.org\/10.2147\/CCID.S24246.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"3509_CR45","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1038\/s41598-020-60738-4","volume":"10","author":"C Friese","year":"2020","unstructured":"Friese C, Harbst K, Borch TH, Westergaard MCW, Pedersen M, Kverneland A, et al. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer. Sci Rep. 2020;10:3914. https:\/\/doi.org\/10.1038\/s41598-020-60738-4.","journal-title":"Sci Rep"},{"key":"3509_CR46","doi-asserted-by":"publisher","unstructured":"Stefanoudakis D, Karopoulou E, Matsas A, Katsampoula GA, Tsarna E, Stamoula E, et al. Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions. Life (Basel, Switzerland) 2024;14. https:\/\/doi.org\/10.3390\/life14030344.","DOI":"10.3390\/life14030344"},{"key":"3509_CR47","doi-asserted-by":"publisher","unstructured":"You W, Zhou Z, Li Z, Yan J, Wang Y. From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor. J Pharm Anal 2025:101322. https:\/\/doi.org\/10.1016\/j.jpha.2025.101322.","DOI":"10.1016\/j.jpha.2025.101322"},{"key":"3509_CR48","doi-asserted-by":"publisher","first-page":"S1164","DOI":"10.1016\/j.annonc.2020.08.2264","volume":"31","author":"DM O\u2019Malley","year":"2020","unstructured":"O\u2019Malley DM, Oaknin A, Monk BJ, Leary A, Selle F, Alexandre J, et al. LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent\/metastatic (R\/M) cervical cancer (CC): Preliminary results of two independent phase II trials. Ann Oncol. 2020;31:S1164\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2264.","journal-title":"Ann Oncol"},{"key":"3509_CR49","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1200\/JCO.21.02067","volume":"40","author":"DM O\u2019Malley","year":"2021","unstructured":"O\u2019Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2021;40:762\u201371. https:\/\/doi.org\/10.1200\/JCO.21.02067.","journal-title":"J Clin Oncol"},{"key":"3509_CR50","doi-asserted-by":"publisher","first-page":"e17522","DOI":"10.1200\/JCO.2024.42.16_suppl.e17522","volume":"42","author":"S Fan","year":"2024","unstructured":"Fan S, Wang T, Zhang Q, Wang J, Su J, Liu Z. Safety and clinical activity of cadonilimab, an anti PD-1\/CTLA-4 bispecific antibody, for patients with persistent, recurrent, or metastatic cervical cancer (R\/M CC): A retrospective, real-world study. J Clin Oncol. 2024;42:e17522\u2013e17522. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e17522.","journal-title":"J Clin Oncol"},{"key":"3509_CR51","doi-asserted-by":"publisher","unstructured":"Ribeiro de Souza B, Oliveira G, Leme G, Brum Reis I, Augusto Tossini Cabral F, Lima Baggio de Paula J, et al. Evaluation of PD-1\/PD-L1 and CTLA-4 immune checkpoints and angiogenic activity in ovarian cancer after oncotherad immunotherapy associated to erythropoietin. J Clin Oncol 2025;40:e17560\u2013e17560. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e17560.","DOI":"10.1200\/JCO.2022.40.16_suppl.e17560"},{"key":"3509_CR52","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1158\/1078-0432.CCR-24-0606","volume":"30","author":"YK Chae","year":"2024","unstructured":"Chae YK, Othus M, Patel SP, Wilkinson KJ, Whitman-Purves EM, Lea J, et al. SWOG\/NCI Phase II Dual Anti\u2013CTLA-4\/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer. Clin Cancer Res. 2024;30:5593\u2013600. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0606.","journal-title":"Clin Cancer Res"},{"key":"3509_CR53","doi-asserted-by":"crossref","unstructured":"Oh MS, Chae YK. Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer. J Immunother 2019;42.","DOI":"10.1097\/CJI.0000000000000244"},{"key":"3509_CR54","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1158\/1538-7445.AM2024-4185","volume":"84","author":"Z Yuan","year":"2024","unstructured":"Yuan Z, Zu G, Sun X, Papasavvas E, Lu L, Cassel J, et al. Abstract 4185: Neutralizing human IFN-\u03b2 combined with anti-human PD-L1 and anti-human CTLA-4 treatment increased control of endometrial tumor growth in a novel HLA-A matched BLT humanized mice. Cancer Res. 2024;84:4185. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-4185.","journal-title":"Cancer Res"},{"key":"3509_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-024-00506-6","volume":"13","author":"M-Y Xu","year":"2024","unstructured":"Xu M-Y, Zeng N, Liu C-Q, Sun J-X, An Y, Zhang S-H, et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy. Exp Hematol Oncol. 2024;13:47. https:\/\/doi.org\/10.1186\/s40164-024-00506-6.","journal-title":"Exp Hematol Oncol"},{"key":"3509_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10555-024-10232-4","volume":"44","author":"CD Yao","year":"2024","unstructured":"Yao CD, Davis KL. Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer. Cancer Metastasis Rev. 2024;44:15. https:\/\/doi.org\/10.1007\/s10555-024-10232-4.","journal-title":"Cancer Metastasis Rev"},{"key":"3509_CR57","doi-asserted-by":"publisher","unstructured":"Cutri-French C, Nasioudis D, George E, Tanyi JL. CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now? Diagnostics 2024;14. https:\/\/doi.org\/10.3390\/diagnostics14080819.","DOI":"10.3390\/diagnostics14080819"},{"key":"3509_CR58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41576-024-00760-8","volume":"26","author":"ZD Smith","year":"2025","unstructured":"Smith ZD, Hetzel S, Meissner A. DNA methylation in mammalian development and disease. Nat Rev Genet. 2025;26:7\u201330. https:\/\/doi.org\/10.1038\/s41576-024-00760-8.","journal-title":"Nat Rev Genet"},{"key":"3509_CR59","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s12013-013-9555-2","volume":"67","author":"H Akhavan-Niaki","year":"2013","unstructured":"Akhavan-Niaki H, Samadani AA. DNA Methylation and Cancer Development: Molecular Mechanism. Cell Biochem Biophys. 2013;67:501\u201313. https:\/\/doi.org\/10.1007\/s12013-013-9555-2.","journal-title":"Cell Biochem Biophys"},{"key":"3509_CR60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41392-023-01537-x","volume":"8","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang Y, Wang C, Wang X. TET (Ten-eleven translocation) family proteins: structure, biological functions and applications. Signal Transduct Target Ther. 2023;8:297. https:\/\/doi.org\/10.1038\/s41392-023-01537-x.","journal-title":"Signal Transduct Target Ther"},{"key":"3509_CR61","doi-asserted-by":"publisher","unstructured":"Schwarzenbach H, Gahan PB. DNA Methylation and Anticancer Drug Resistance in Gynecological Tumors . Cancer Screen Prev n.d.;1:47\u201363. https:\/\/doi.org\/10.14218\/CSP.2022.00004.","DOI":"10.14218\/CSP.2022.00004"},{"key":"3509_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00432-019-03093-w","volume":"146","author":"FKF Kommoss","year":"2020","unstructured":"Kommoss FKF, Stichel D, Schrimpf D, Kriegsmann M, Tessier-Cloutier B, Talhouk A, et al. DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. J Cancer Res Clin Oncol. 2020;146:97\u2013104. https:\/\/doi.org\/10.1007\/s00432-019-03093-w.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3509_CR63","doi-asserted-by":"publisher","unstructured":"Mehdi A, Rabbani SA. Role of Methylation in Pro- and Anti-Cancer Immunity. Cancers (Basel) 2021;13. https:\/\/doi.org\/10.3390\/cancers13030545.","DOI":"10.3390\/cancers13030545"},{"key":"3509_CR64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11523-024-01041-4","volume":"19","author":"JM Ressler","year":"2024","unstructured":"Ressler JM, Tomasich E, Hatziioannou T, Ringl H, Heller G, Silmbrod R, et al. DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma. Target Oncol. 2024;19:263\u201375. https:\/\/doi.org\/10.1007\/s11523-024-01041-4.","journal-title":"Target Oncol"},{"key":"3509_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-019-0081-6","volume":"4","author":"W Xu","year":"2019","unstructured":"Xu W, Xu M, Wang L, Zhou W, Xiang R, Shi Y, et al. Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers. Signal Transduct Target Ther. 2019;4:55. https:\/\/doi.org\/10.1038\/s41392-019-0081-6.","journal-title":"Signal Transduct Target Ther"},{"key":"3509_CR66","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.1038\/srep06331","volume":"4","author":"D Ma","year":"2014","unstructured":"Ma D, Jiang C, Hu X, Liu H, Li Q, Li T, et al. Methylation Patterns of the IFN-\u03b3 Gene in Cervical Cancer Tissues. Sci Rep. 2014;4:6331. https:\/\/doi.org\/10.1038\/srep06331.","journal-title":"Sci Rep"},{"key":"3509_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044952","volume":"7","author":"A Hasim","year":"2012","unstructured":"Hasim A, Abudula M, Aimiduo R, Ma J-Q, Jiao Z, Akula G, et al. Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women. PLoS ONE. 2012;7: e44952. https:\/\/doi.org\/10.1371\/journal.pone.0044952.","journal-title":"PLoS ONE"},{"key":"3509_CR68","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3892\/br.2013.69","volume":"1","author":"Y Wang","year":"2013","unstructured":"Wang Y, Liu X, Li Y, Li O. The paradox of IL-10-mediated modulation in cervical cancer (Review). Biomed Rep. 2013;1:347\u201351. https:\/\/doi.org\/10.3892\/br.2013.69.","journal-title":"Biomed Rep"},{"key":"3509_CR69","doi-asserted-by":"crossref","unstructured":"Liu B, Zhai J, Wang W, Liu T, Liu C, Zhu X, et al. Identification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer. Front Mol Biosci 2022;9.","DOI":"10.3389\/fmolb.2022.872932"},{"key":"3509_CR70","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.3892\/or.2019.7388","volume":"42","author":"L Zhang","year":"2019","unstructured":"Zhang L, Tian S, Pei M, Zhao M, Wang L, Jiang Y, et al. Crosstalk between histone modification and DNA methylation orchestrates the epigenetic regulation of the costimulatory factors, Tim-3 and galectin-9, in cervical cancer. Oncol Rep. 2019;42:2655\u201369. https:\/\/doi.org\/10.3892\/or.2019.7388.","journal-title":"Oncol Rep"},{"key":"3509_CR71","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s13167-024-00359-3","volume":"15","author":"W Jia","year":"2024","unstructured":"Jia W, Li N, Wang J, Gong X, Ouedraogo SY, Wang Y, et al. Immune-related gene methylation prognostic instrument for stratification and targeted treatment of ovarian cancer patients toward advanced 3PM approach. EPMA J. 2024;15:375\u2013404. https:\/\/doi.org\/10.1007\/s13167-024-00359-3.","journal-title":"EPMA J"},{"key":"3509_CR72","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1200\/JCO.2020.38.15_suppl.6025","volume":"38","author":"D Matei","year":"2025","unstructured":"Matei D, Pant A, Moroney JW, Fleming GF, Tanner E, Swetzig WM, et al. Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer. J Clin Oncol. 2025;38:6025. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.6025.","journal-title":"J Clin Oncol"},{"key":"3509_CR73","doi-asserted-by":"publisher","unstructured":"Chiappinelli KB, Baylin SB. Inhibiting DNA methylation improves antitumor immunity in ovarian cancer. J Clin Invest 2022;132. https:\/\/doi.org\/10.1172\/JCI160186.","DOI":"10.1172\/JCI160186"},{"key":"3509_CR74","doi-asserted-by":"publisher","first-page":"5119411","DOI":"10.1155\/2022\/5119411","volume":"2022","author":"F Dai","year":"2022","unstructured":"Dai F, Wu J, Deng Z, Li H, Tan W, Yuan M, et al. Integrated Bioinformatic Analysis of DNA Methylation and Immune Infiltration in Endometrial Cancer. Biomed Res Int. 2022;2022:5119411. https:\/\/doi.org\/10.1155\/2022\/5119411.","journal-title":"Biomed Res Int"},{"key":"3509_CR75","doi-asserted-by":"publisher","unstructured":"Yao-Chung L, Junsu K, Emiliano F, Zhijian X, V. LY, Y. FM, et al. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy. N Engl J Med 2022;386:1998\u20132010. https:\/\/doi.org\/10.1056\/NEJMoa2119771.","DOI":"10.1056\/NEJMoa2119771"},{"key":"3509_CR76","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41573-024-01080-6","volume":"24","author":"M-M Zhou","year":"2025","unstructured":"Zhou M-M, Cole PA. Targeting lysine acetylation readers and writers. Nat Rev Drug Discov. 2025;24:112\u201333. https:\/\/doi.org\/10.1038\/s41573-024-01080-6.","journal-title":"Nat Rev Drug Discov"},{"key":"3509_CR77","doi-asserted-by":"crossref","unstructured":"Dai Q, Ye Y. Development and Validation of a Novel Histone Acetylation-Related Gene Signature for Predicting the Prognosis of Ovarian Cancer. Front Cell Dev Biol 2022;10.","DOI":"10.3389\/fcell.2022.793425"},{"key":"3509_CR78","doi-asserted-by":"publisher","unstructured":"Liu S, Chang W, Jin Y, Feng C, Wu S, He J, et al. The function of histone acetylation in cervical cancer development. Biosci Rep 2019;39:BSR20190527. https:\/\/doi.org\/10.1042\/BSR20190527.","DOI":"10.1042\/BSR20190527"},{"key":"3509_CR79","doi-asserted-by":"crossref","unstructured":"Lu J, He X, Zhang L, Zhang R, Li W. Acetylation in Tumor Immune Evasion Regulation. Front Pharmacol 2021;12.","DOI":"10.3389\/fphar.2021.771588"},{"key":"3509_CR80","doi-asserted-by":"publisher","unstructured":"Lu X, Jin P, Tang Q, Zhou M, Xu H, Su C, et al. NAD(+) Metabolism Reprogramming Drives SIRT1-Dependent Deacetylation Inducing PD-L1 Nuclear Localization in Cervical Cancer. Adv Sci (Weinheim, Baden-Wurttemberg, Ger 2025:e2412109. https:\/\/doi.org\/10.1002\/advs.202412109.","DOI":"10.1002\/advs.202412109"},{"key":"3509_CR81","doi-asserted-by":"publisher","unstructured":"Qi X, Zhou J, Wang X, Shen Y, Cao Y, Jiang L, et al. HPV E6\/E7-Induced Acetylation of a Peptide Encoded by a Long Non-Coding RNA Inhibits Ferroptosis to Promote the Malignancy of Cervical Cancer. Adv Sci (Weinheim, Baden-Wurttemberg, Ger 2025;12:e2414018. https:\/\/doi.org\/10.1002\/advs.202414018.","DOI":"10.1002\/advs.202414018"},{"key":"3509_CR82","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2147\/OTT.S491130","volume":"18","author":"P-W Liu","year":"2025","unstructured":"Liu P-W, Liu Z-Y, Deng S-J, Zhang X, Wang Z-B, Wu N-Y, et al. A Pyroptosis-Related LncRNA Signature for Predicting Prognosis, Immune Features and Drug Sensitivity in Ovarian Cancer. Onco Targets Ther. 2025;18:585\u2013601. https:\/\/doi.org\/10.2147\/OTT.S491130.","journal-title":"Onco Targets Ther"},{"key":"3509_CR83","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13048-024-01449-6","volume":"17","author":"X Wang","year":"2024","unstructured":"Wang X, Li X, Wei L, Yu Y, Hazaisihan Y, Tao L, et al. Acetylation model predicts prognosis of patients and affects immune microenvironment infiltration in epithelial ovarian carcinoma. J Ovarian Res. 2024;17:150. https:\/\/doi.org\/10.1186\/s13048-024-01449-6.","journal-title":"J Ovarian Res"},{"key":"3509_CR84","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/07853890.2015.1043140","volume":"47","author":"J Borley","year":"2015","unstructured":"Borley J, Brown R. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Ann Med. 2015;47:359\u201369. https:\/\/doi.org\/10.3109\/07853890.2015.1043140.","journal-title":"Ann Med"},{"key":"3509_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.119126","volume":"338","author":"J Zhou","year":"2025","unstructured":"Zhou J, Guo Z, Peng X, Wu B, Meng Q, Lu X, et al. Chrysotoxine regulates ferroptosis and the PI3K\/AKT\/mTOR pathway to prevent cervical cancer. J Ethnopharmacol. 2025;338: 119126. https:\/\/doi.org\/10.1016\/j.jep.2024.119126.","journal-title":"J Ethnopharmacol"},{"key":"3509_CR86","doi-asserted-by":"publisher","unstructured":"Li C-J, Chiu Y-H, Chang C, Chang Y-CI, Sheu JJ-C, Chiang A-J. Acetyl Coenzyme A Synthase 2 Acts as a Prognostic Biomarker Associated with Immune Infiltration in Cervical Squamous Cell Carcinoma. Cancers (Basel) 2021;13. https:\/\/doi.org\/10.3390\/cancers13133125.","DOI":"10.3390\/cancers13133125"},{"key":"3509_CR87","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1007\/s10528-024-10704-w","volume":"62","author":"C Ye","year":"2024","unstructured":"Ye C, Cheng Y, Qian X, Zhong B, Ma J, Guo H. The CDK4\/6 Inhibitor Palbociclib Induces Cell Senescence of High-grade Serous Ovarian Cancer Through Acetylation of p53. Biochem Genet. 2024;62:5115\u201328. https:\/\/doi.org\/10.1007\/s10528-024-10704-w.","journal-title":"Biochem Genet"},{"key":"3509_CR88","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1097\/IGC.0000000000001334","volume":"28","author":"X Zhu","year":"2018","unstructured":"Zhu X, Zhao L, Lang J. The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2018;28:1514\u20139. https:\/\/doi.org\/10.1097\/IGC.0000000000001334.","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"3509_CR89","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1158\/1055-9965.EPI-22-0941","volume":"32","author":"C Wang","year":"2023","unstructured":"Wang C, Block MS, Cunningham JM, Sherman ME, McCauley BM, Armasu SM, et al. Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma. Cancer Epidemiol Biomarkers Prev a Publ Am Assoc Cancer Res Cosponsored by Am Soc Prev Oncol. 2023;32:542\u20139. https:\/\/doi.org\/10.1158\/1055-9965.EPI-22-0941.","journal-title":"Cancer Epidemiol Biomarkers Prev a Publ Am Assoc Cancer Res Cosponsored by Am Soc Prev Oncol"},{"key":"3509_CR90","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3892\/ijo.2012.1508","volume":"41","author":"K-M Kim","year":"2012","unstructured":"Kim K-M, Song M-H, Kim M-J, Daudi S, Miliotto A, Old L, et al. A novel cancer\/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation. Int J Oncol. 2012;41:1139\u201347. https:\/\/doi.org\/10.3892\/ijo.2012.1508.","journal-title":"Int J Oncol"},{"key":"3509_CR91","doi-asserted-by":"publisher","first-page":"8112","DOI":"10.1038\/s41598-022-11415-1","volume":"12","author":"X Yang","year":"2022","unstructured":"Yang X, Chen Y, Li M, Zhu W. ERBB3 methylation and immune infiltration in tumor microenvironment of cervical cancer. Sci Rep. 2022;12:8112. https:\/\/doi.org\/10.1038\/s41598-022-11415-1.","journal-title":"Sci Rep"},{"key":"3509_CR92","doi-asserted-by":"publisher","first-page":"1208223","DOI":"10.3389\/fimmu.2023.1208223","volume":"14","author":"J Hao","year":"2023","unstructured":"Hao J, Liu T, Xiu Y, Yuan H, Xu D. High DNA methylation age deceleration defines an aggressive phenotype with immunoexclusion environments in endometrial carcinoma. Front Immunol. 2023;14:1208223. https:\/\/doi.org\/10.3389\/fimmu.2023.1208223.","journal-title":"Front Immunol"},{"key":"3509_CR93","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12935-021-02038-z","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu J, Ji C, Wang Y, Zhang C, Zhu H. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer. Cancer Cell Int. 2021;21:365. https:\/\/doi.org\/10.1186\/s12935-021-02038-z.","journal-title":"Cancer Cell Int"},{"key":"3509_CR94","doi-asserted-by":"crossref","unstructured":"Liu J, Zhu W, Xia L, Zhu Q, Mao Y, Shen Y, et al. Identification of CAPG as a potential prognostic biomarker associated with immune cell infiltration and ferroptosis in uterine corpus endometrial carcinoma. Front Endocrinol (Lausanne) 2024;15.","DOI":"10.3389\/fendo.2024.1452219"},{"key":"3509_CR95","doi-asserted-by":"publisher","unstructured":"Kim J, Kong JK, Yang W, Cho H, Chay DB, Lee BH, et al. DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer. Cancers (Basel) 2018;10. https:\/\/doi.org\/10.3390\/cancers10090279.","DOI":"10.3390\/cancers10090279"},{"key":"3509_CR96","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/carcin\/bgac048","volume":"43","author":"M Tan","year":"2022","unstructured":"Tan M, Wang S, Li F, Xu H, Gao J, Zhu L. A methylation-driven genes prognostic signature and the immune microenvironment in epithelial ovarian cancer. Carcinogenesis. 2022;43:635\u201346. https:\/\/doi.org\/10.1093\/carcin\/bgac048.","journal-title":"Carcinogenesis"},{"key":"3509_CR97","doi-asserted-by":"publisher","unstructured":"Ma J, Yang D, Ma X-X. Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer. Aging (Albany NY) 2021;13:16287\u2013315. https:\/\/doi.org\/10.18632\/aging.203157.","DOI":"10.18632\/aging.203157"},{"key":"3509_CR98","doi-asserted-by":"publisher","unstructured":"Chen X, Hao Y, Liu Y, Zhong S, You Y, Ao K, et al. NAT10\/ac4C\/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer. Adv Sci (Weinheim, Baden-Wurttemberg, Ger 2023;10:e2302705. https:\/\/doi.org\/10.1002\/advs.202302705.","DOI":"10.1002\/advs.202302705"},{"key":"3509_CR99","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13578-023-01149-6","volume":"13","author":"J Wang","year":"2023","unstructured":"Wang J, Ling D, Shi L, Li H, Peng M, Wen H, et al. METTL3-mediated m6A methylation regulates ovarian cancer progression by recruiting myeloid-derived suppressor cells. Cell Biosci. 2023;13:202. https:\/\/doi.org\/10.1186\/s13578-023-01149-6.","journal-title":"Cell Biosci"},{"key":"3509_CR100","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1186\/s12885-022-10490-x","volume":"22","author":"F Fang","year":"2022","unstructured":"Fang F, Wang P, Huang H, Ye M, Liu X, Li Q. m(6)A RNA methylation regulator-based signature for prognostic prediction and its potential immunological role in uterine corpus endometrial carcinoma. BMC Cancer. 2022;22:1364. https:\/\/doi.org\/10.1186\/s12885-022-10490-x.","journal-title":"BMC Cancer"},{"key":"3509_CR101","doi-asserted-by":"crossref","unstructured":"Gu J, Bi F. Significance of N6-Methyladenosine RNA Methylation Regulators in Immune Infiltrates of Ovarian Cancer. Front Genet 2021;12.","DOI":"10.3389\/fgene.2021.671179"},{"key":"3509_CR102","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.gendis.2023.01.021","volume":"10","author":"K Li","year":"2023","unstructured":"Li K, Shu S, Zou J, Li M, Liu Z. m(6)A regulator-mediated methylation modification patterns and tumor immune microenvironment characterization in endometrial cancer. Genes Dis. 2023;10:2278\u201381. https:\/\/doi.org\/10.1016\/j.gendis.2023.01.021.","journal-title":"Genes Dis"},{"key":"3509_CR103","doi-asserted-by":"crossref","unstructured":"Liu J, Chen C, Wang Y, Qian C, Wei J, Xing Y, et al. Comprehensive of N1-Methyladenosine Modifications Patterns and Immunological Characteristics in Ovarian Cancer. Front Immunol 2021;12.","DOI":"10.3389\/fimmu.2021.746647"},{"key":"3509_CR104","doi-asserted-by":"crossref","unstructured":"Zhang W, Xiao P, Tang J, Wang R, Wang X, Wang F, et al. m6A Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment. Front Immunol 2022;13.","DOI":"10.3389\/fimmu.2022.888650"},{"key":"3509_CR105","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.7150\/jca.103243","volume":"16","author":"P Rajendran","year":"2025","unstructured":"Rajendran P, Prasad M, Ali EM, Sekar R, AlZahrani AM, Karobari MI, et al. Molecular insight into histone methylation as a novel target for oral squamous cell carcinoma: future hope in personalised medicine. J Cancer. 2025;16:1575\u201390. https:\/\/doi.org\/10.7150\/jca.103243.","journal-title":"J Cancer"},{"key":"3509_CR106","doi-asserted-by":"publisher","unstructured":"Bu S, Ye T, Gao H, Song H, Zhu Y. Histone methylation and acetylation in cancer: mechanism, progression, and targets 2025;27:29\u201343. https:\/\/doi.org\/10.1515\/oncologie-2024-0324.","DOI":"10.1515\/oncologie-2024-0324"},{"key":"3509_CR107","doi-asserted-by":"publisher","unstructured":"Xiao C, Fan T, Zheng Y, Tian H, Deng Z, Liu J, et al. H3K4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy. J Immunother Cancer 2023;11. https:\/\/doi.org\/10.1136\/jitc-2022-005693.","DOI":"10.1136\/jitc-2022-005693"},{"key":"3509_CR108","doi-asserted-by":"publisher","unstructured":"Sun W, Lv S, Li H, Cui W, Wang L. Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors. Genes (Basel) 2018;9. https:\/\/doi.org\/10.3390\/genes9120633.","DOI":"10.3390\/genes9120633"},{"key":"3509_CR109","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12885-017-3257-x","volume":"17","author":"X Li","year":"2017","unstructured":"Li X. Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer. BMC Cancer. 2017;17:252. https:\/\/doi.org\/10.1186\/s12885-017-3257-x.","journal-title":"BMC Cancer"},{"key":"3509_CR110","doi-asserted-by":"publisher","first-page":"030006052513283","DOI":"10.1177\/03000605251328301","volume":"53","author":"Xu Su Luyang","year":"2025","unstructured":"Su Luyang Xu, Ren RY, Shixia Z, Liyun S, Cuiqiao M, et al. 5-Methylcytosine methylation predicts cervical cancer prognosis, shaping immune cell infiltration. J Int Med Res. 2025;53:03000605251328301. https:\/\/doi.org\/10.1177\/03000605251328301.","journal-title":"J Int Med Res"},{"key":"3509_CR111","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13048-024-01358-8","volume":"17","author":"H Yang","year":"2024","unstructured":"Yang H, Sui L, Cai C, Chu H, Diao Y. SETDB1 promotes progression through upregulation of SF3B4 expression and regulates the immunity in ovarian cancer. J Ovarian Res. 2024;17:34. https:\/\/doi.org\/10.1186\/s13048-024-01358-8.","journal-title":"J Ovarian Res"},{"key":"3509_CR112","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/2326-6066.CIR-22-0088","volume":"10","author":"H Liu","year":"2022","unstructured":"Liu H, Lin J, Zhou W, Moses R, Dai Z, Kossenkov AV, et al. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. Cancer Immunol Res. 2022;10:1028\u201338. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0088.","journal-title":"Cancer Immunol Res"},{"key":"3509_CR113","doi-asserted-by":"publisher","first-page":"8205","DOI":"10.1038\/s41598-025-92666-6","volume":"15","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Fu Y, Liu F, Yan S, Yu R. Appraising histone H4 lysine 5 lactylation as a novel biomarker in breast cancer. Sci Rep. 2025;15:8205. https:\/\/doi.org\/10.1038\/s41598-025-92666-6.","journal-title":"Sci Rep"},{"key":"3509_CR114","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s13258-024-01554-2","volume":"46","author":"J Zhou","year":"2024","unstructured":"Zhou J, Ma X, Liu X, Liu Y, Fu J, Qi Y, et al. The impact of histone lactylation on the tumor microenvironment and metabolic pathways and its potential in cancer therapy. Genes Genomics. 2024;46:991\u20131011. https:\/\/doi.org\/10.1007\/s13258-024-01554-2.","journal-title":"Genes Genomics"},{"key":"3509_CR115","doi-asserted-by":"crossref","unstructured":"Cai Q, Deng W, Zou Y, Chen Z-S, Tang H. Histone lactylation as a driver of metabolic reprogramming and immune evasion. Med Rev 2024.","DOI":"10.1515\/mr-2024-0091"},{"key":"3509_CR116","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/07357907.2024.2430283","volume":"43","author":"X Hu","year":"2025","unstructured":"Hu X, Zhenqiang H, Li L. LDHB Mediates Histone Lactylation to Activate PD-L1 and Promote Ovarian Cancer Immune Escape. Cancer Invest. 2025;43:70\u20139. https:\/\/doi.org\/10.1080\/07357907.2024.2430283.","journal-title":"Cancer Invest"},{"key":"3509_CR117","doi-asserted-by":"publisher","unstructured":"Yang X, Zhang W, Zhu W. Profiling of immune responses by lactate modulation in cervical cancer reveals key features driving clinical outcome. Heliyon 2023;9. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e14896.","DOI":"10.1016\/j.heliyon.2023.e14896"},{"key":"3509_CR118","doi-asserted-by":"publisher","unstructured":"Xu X, Pan X, Fan Z, Xia J, Ren X. Lactate dehydrogenase B as a metabolism-related marker for immunotherapy in head and neck squamous cell carcinoma. Cell Signal 2024;120:111200. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111200.","DOI":"10.1016\/j.cellsig.2024.111200"},{"key":"3509_CR119","doi-asserted-by":"publisher","unstructured":"Xiang H, Tang H, He Q, Sun J, Yang Y, Kong L, et al. NDUFA8 is transcriptionally regulated by EP300\/H3K27ac and promotes mitochondrial respiration to support proliferation and inhibit apoptosis in cervical cancer. Biochem Biophys Res Commun 2024;693:149374. https:\/\/doi.org\/10.1016\/j.bbrc.2023.149374.","DOI":"10.1016\/j.bbrc.2023.149374"},{"key":"3509_CR120","doi-asserted-by":"crossref","unstructured":"Huang W, Kong F, Li R, Chen X, Wang K. Emerging Roles of m6A RNA Methylation Regulators in Gynecological Cancer. Front Oncol 2022;12.","DOI":"10.3389\/fonc.2022.827956"},{"key":"3509_CR121","doi-asserted-by":"publisher","unstructured":"Li J, Zhang H, Wang H. N1-methyladenosine modification in cancer biology: Current status and future perspectives. Comput Struct Biotechnol J 2022;20:6578\u201385. https:\/\/doi.org\/10.1016\/j.csbj.2022.11.045.","DOI":"10.1016\/j.csbj.2022.11.045"},{"key":"3509_CR122","doi-asserted-by":"publisher","unstructured":"Zhang C, Liu N. N6-methyladenosine (m6A) modification in gynecological malignancies. J Cell Physiol 2022;237:3465\u201379. https:\/\/doi.org\/10.1002\/jcp.30828.","DOI":"10.1002\/jcp.30828"},{"key":"3509_CR123","doi-asserted-by":"crossref","unstructured":"He W, Hong X, Chen G, Luo X, Lin Y. RNA modifications in gynecological cancer: current status and future directions. Front Med 2024;11.","DOI":"10.3389\/fmed.2024.1314075"},{"key":"3509_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.972341","volume":"13","author":"P Zheng","year":"2022","unstructured":"Zheng P, Li N, Zhan X. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis. Front Endocrinol (Lausanne). 2022;13: 972341. https:\/\/doi.org\/10.3389\/fendo.2022.972341.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3509_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.976107","volume":"13","author":"H Ji","year":"2022","unstructured":"Ji H, Zhang J-A, Liu H, Li K, Wang Z-W, Zhu X. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer. Front Immunol. 2022;13: 976107. https:\/\/doi.org\/10.3389\/fimmu.2022.976107.","journal-title":"Front Immunol"},{"key":"3509_CR126","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1080\/15476286.2024.2408707","volume":"21","author":"Y Gao","year":"2024","unstructured":"Gao Y, Qi G, Yu L. m6A modification of RNA in cervical cancer: role and clinical perspectives. RNA Biol. 2024;21:994\u20131006. https:\/\/doi.org\/10.1080\/15476286.2024.2408707.","journal-title":"RNA Biol"},{"key":"3509_CR127","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s41556-018-0174-4","volume":"20","author":"J Liu","year":"2018","unstructured":"Liu J, Eckert MA, Harada BT, Liu S-M, Lu Z, Yu K, et al. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018;20:1074\u201383. https:\/\/doi.org\/10.1038\/s41556-018-0174-4.","journal-title":"Nat Cell Biol"},{"key":"3509_CR128","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s13273-023-00360-3","volume":"20","author":"S Chen","year":"2024","unstructured":"Chen S, Chen Y, Yu L, Hu X. YTHDC1 inhibits cell proliferation and angiogenesis in cervical cancer by regulating m6A modification of SOCS4 mRNA. Mol Cell Toxicol. 2024;20:533\u201340. https:\/\/doi.org\/10.1007\/s13273-023-00360-3.","journal-title":"Mol Cell Toxicol"},{"key":"3509_CR129","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","volume":"19","author":"F Lyko","year":"2018","unstructured":"Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19:81\u201392. https:\/\/doi.org\/10.1038\/nrg.2017.80.","journal-title":"Nat Rev Genet"},{"key":"3509_CR130","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1158\/0008-5472.CAN-18-4018","volume":"79","author":"M Travers","year":"2019","unstructured":"Travers M, Brown SM, Dunworth M, Holbert CE, Wiehagen KR, Bachman KE, et al. DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer. Cancer Res. 2019;79:3445\u201354. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-4018.","journal-title":"Cancer Res"},{"key":"3509_CR131","doi-asserted-by":"publisher","DOI":"10.1007\/s10528-025-11038-x","author":"SC Tyagi","year":"2025","unstructured":"Tyagi SC, Smolenkova I, Zheng Y, Singh M. Epigenetic Control of Hyperuricemia and Gout by Gene Writer DNMT1 and RNA Editor ADAR1: Mechanism of Gout and Amyloid Dissolution in Down Syndrome. Biochem Genet. 2025. https:\/\/doi.org\/10.1007\/s10528-025-11038-x.","journal-title":"Biochem Genet"},{"key":"3509_CR132","doi-asserted-by":"crossref","unstructured":"Uchida H, Ito S. Differential regulation of expression of RNA-editing enzymes, ADAR1 and ADAR2, by 5-aza-2\u2032-deoxycytidine and trichostatin A in human neuronal SH-SY5Y cells. Neuroreport 2015;26.","DOI":"10.1097\/WNR.0000000000000474"},{"key":"3509_CR133","doi-asserted-by":"publisher","unstructured":"Gomez S, Cox OL, Walker RR 3rd, Rentia U, Hadley M, Arthofer E, et al. Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer. J Immunother Cancer 2022;10. https:\/\/doi.org\/10.1136\/jitc-2022-004974.","DOI":"10.1136\/jitc-2022-004974"},{"key":"3509_CR134","unstructured":"Cox OL. The Role of TP53, ADAR1, and T Cells in the Interferon Response to DNMTi Therapy in Ovarian Cancer Model 2024."},{"key":"3509_CR135","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13402-023-00885-8","volume":"47","author":"J Guo","year":"2024","unstructured":"Guo J, Tang B, Fu J, Zhu X, Xie W, Wang N, et al. High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I\/DNMT3A\/CD8 modulatory axis in mismatch repair-deficient endometrial cancer. Cell Oncol (Dordrecht, Netherlands). 2024;47:573\u201385. https:\/\/doi.org\/10.1007\/s13402-023-00885-8.","journal-title":"Cell Oncol (Dordrecht, Netherlands)"},{"key":"3509_CR136","doi-asserted-by":"publisher","unstructured":"Grau Bejar JF, Yaniz Galende E, Zeng Q, Genestie C, Rouleau E, de Bruyn M, et al. Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer. J Immunother Cancer 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-009143.","DOI":"10.1136\/jitc-2024-009143"},{"key":"3509_CR137","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673332285241104091609","author":"Y Chen","year":"2025","unstructured":"Chen Y, Su J, Li S, Chen F, Zhang Y, Wang X, et al. Structural Modifications and Prospects of Histone Deacetylase (HDAC) Inhibitors in Cancer. Curr Med Chem. 2025. https:\/\/doi.org\/10.2174\/0109298673332285241104091609.","journal-title":"Curr Med Chem"},{"key":"3509_CR138","doi-asserted-by":"publisher","unstructured":"Psilopatis I, Pergaris A, Giaginis C, Theocharis S. Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma. Dis Markers 2021;2021:7850688. https:\/\/doi.org\/10.1155\/2021\/7850688.","DOI":"10.1155\/2021\/7850688"},{"key":"3509_CR139","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12929-014-0111-1","volume":"22","author":"Z Huang","year":"2015","unstructured":"Huang Z, Peng S, Knoff J, Lee SY, Yang B, Wu T-C, et al. Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model. J Biomed Sci. 2015;22:7. https:\/\/doi.org\/10.1186\/s12929-014-0111-1.","journal-title":"J Biomed Sci"},{"key":"3509_CR140","doi-asserted-by":"publisher","unstructured":"Mora-Garc\u00eda M de L, Duenas-Gonz\u00e1lez A, Hern\u00e1ndez-Montes J, De la Cruz-Hern\u00e1ndez E, P\u00e9rez-C\u00e1rdenas E, Weiss-Steider B, et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med 2006;4:55. https:\/\/doi.org\/10.1186\/1479-5876-4-55.","DOI":"10.1186\/1479-5876-4-55"},{"issue":"Suppl 1","key":"3509_CR141","doi-asserted-by":"publisher","first-page":"S540","DOI":"10.1007\/s12032-010-9700-3","volume":"28","author":"J Coronel","year":"2011","unstructured":"Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, Gonz\u00e1lez-Fierro A, de la Cruz-Hernandez E, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results Med Oncol. 2011;28(Suppl 1):S540\u20136. https:\/\/doi.org\/10.1007\/s12032-010-9700-3.","journal-title":"Preliminary results Med Oncol"},{"key":"3509_CR142","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/cam4.3337","volume":"10","author":"TR McCaw","year":"2021","unstructured":"McCaw TR, Goel N, Brooke DJ, Katre AA, Londo\u00f1o AI, Smith HJ, et al. Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer. Cancer Med. 2021;10:709\u201317. https:\/\/doi.org\/10.1002\/cam4.3337.","journal-title":"Cancer Med"},{"key":"3509_CR143","doi-asserted-by":"publisher","unstructured":"Tang Z, Ding S, Huang H, Luo P, Qing B, Zhang S, et al. HDAC1 triggers the proliferation and migration of breast cancer cells via upregulation of interleukin-8 2017;398:1347\u201356. https:\/\/doi.org\/10.1515\/hsz-2017-0155.","DOI":"10.1515\/hsz-2017-0155"},{"key":"3509_CR144","doi-asserted-by":"publisher","unstructured":"Gatla HR, Zou Y, Uddin MM, Vancurova I. Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells. Oncotarget 2017;8:70798\u2013810. https:\/\/doi.org\/10.18632\/oncotarget.19990.","DOI":"10.18632\/oncotarget.19990"},{"key":"3509_CR145","doi-asserted-by":"publisher","unstructured":"Qiu J, Xu Q, Panah T, Morshed AKMH, Wang X, Zhou F, et al. Reactive oxygen species mediate ovarian cancer development, platinum resistance, and angiogenesis via CXCL8 and GSK-3\u03b2\/p70S6K1 axis. Genes Dis 2025;12:101378. https:\/\/doi.org\/10.1016\/j.gendis.2024.101378.","DOI":"10.1016\/j.gendis.2024.101378"},{"key":"3509_CR146","doi-asserted-by":"publisher","unstructured":"Ghahfarrokhi SSM, Karimi P, Mahdigholi F-S, Haji Abdolvahab M. Vaccination and personalized cancer vaccines focusing on common cancers in women: A narrative review. Pathol - Res Pract 2025;270:155983. https:\/\/doi.org\/10.1016\/j.prp.2025.155983.","DOI":"10.1016\/j.prp.2025.155983"},{"key":"3509_CR147","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1065369","volume":"5","author":"JK Peper","year":"2016","unstructured":"Peper JK, B\u00f6sm\u00fcller H-C, Schuster H, G\u00fcckel B, H\u00f6rzer H, Roehle K, et al. HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. Oncoimmunology. 2016;5: e1065369. https:\/\/doi.org\/10.1080\/2162402X.2015.1065369.","journal-title":"Oncoimmunology"},{"key":"3509_CR148","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/hum.2012.143","volume":"24","author":"D-G Song","year":"2013","unstructured":"Song D-G, Ye Q, Santoro S, Fang C, Best A, Powell DJJ. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum Gene Ther. 2013;24:295\u2013305. https:\/\/doi.org\/10.1089\/hum.2012.143.","journal-title":"Hum Gene Ther"},{"key":"3509_CR149","doi-asserted-by":"publisher","unstructured":"Yang Z, Chu B, Tu Y, Li L, Chen D, Huang S, et al. Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy. Pharmacol Res 2024;206:107271. https:\/\/doi.org\/10.1016\/j.phrs.2024.107271.","DOI":"10.1016\/j.phrs.2024.107271"},{"key":"3509_CR150","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1158\/1538-7445.AM2018-1395","volume":"78","author":"AP Srivastava","year":"2018","unstructured":"Srivastava AP, Moufarrij SM, Hadley M, Chisholm S, Lopez-Acevedo M, Villagra A, et al. Abstract 1395: HDAC6 and DNMT inhibition affect immunogenicity of ovarian cancer cells: A rationale for combining epigenetic and immune therapy in ovarian cancer. Cancer Res. 2018;78:1395. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-1395.","journal-title":"Cancer Res"},{"key":"3509_CR151","doi-asserted-by":"publisher","unstructured":"Turner TB, Meza-Perez S, Londo\u00f1o A, Katre A, Peabody JE, Smith HJ, et al. Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Oncotarget 2017;8:44159\u201370. https:\/\/doi.org\/10.18632\/oncotarget.17395.","DOI":"10.18632\/oncotarget.17395"},{"key":"3509_CR152","doi-asserted-by":"publisher","unstructured":"Cox OL, Gomez S, Grundy EE, Chiappinelli KB. Combination epigenetic therapy activates immune cells in a murine model of ovarian cancer. J Immunol 2023;210:245.21\u2013245.21. https:\/\/doi.org\/10.4049\/jimmunol.210.Supp.245.21.","DOI":"10.4049\/jimmunol.210.Supp.245.21"},{"key":"3509_CR153","doi-asserted-by":"publisher","first-page":"5043","DOI":"10.1074\/jbc.M116.771014","volume":"292","author":"HR Gatla","year":"2017","unstructured":"Gatla HR, Zou Y, Uddin MM, Singha B, Bu P, Vancura A, et al. Histone Deacetylase (HDAC) Inhibition Induces I\u03baB Kinase (IKK)-dependent Interleukin-8\/CXCL8 Expression in Ovarian Cancer Cells. J Biol Chem. 2017;292:5043\u201354. https:\/\/doi.org\/10.1074\/jbc.M116.771014.","journal-title":"J Biol Chem"},{"key":"3509_CR154","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.celrep.2016.09.003","volume":"17","author":"M Kim","year":"2016","unstructured":"Kim M, Lu F, Zhang Y. Loss of HDAC-Mediated Repression and Gain of NF-\u03baB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer. Cell Rep. 2016;17:275\u201388. https:\/\/doi.org\/10.1016\/j.celrep.2016.09.003.","journal-title":"Cell Rep"},{"key":"3509_CR155","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ygyno.2020.11.008","volume":"160","author":"MS Fejzo","year":"2021","unstructured":"Fejzo MS, Chen H-W, Anderson L, McDermott MSJ, Karlan B, Konecny GE, et al. Analysis in epithelial ovarian cancer identifies <em>KANSL1<\/em> as a biomarker and target gene for immune response and HDAC inhibition. Gynecol Oncol. 2021;160:539\u201346. https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.008.","journal-title":"Gynecol Oncol"},{"key":"3509_CR156","unstructured":"Gomez SA. Epigenetic Activation of Transposable Elements to Reverse Immune Evasion in Ovarian Cancer 2023."},{"key":"3509_CR157","doi-asserted-by":"publisher","DOI":"10.1101\/2023.10.03.560719","author":"Z Kang","year":"2023","unstructured":"Kang Z, Fu P, Ma H, Li T, Lu K, Liu J, et al. Distinct functions of EHMT1 and EHMT2 in cancer chemotherapy and immunotherapy. BioRxiv Prepr Serv Biol. 2023. https:\/\/doi.org\/10.1101\/2023.10.03.560719.","journal-title":"BioRxiv Prepr Serv Biol"},{"key":"3509_CR158","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s12325-020-01379-x","volume":"37","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Jacobs I, Sharma S, Scappaticci F, Paul TA, Jensen-Pergakes K, et al. The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. Adv Ther. 2020;37:3059\u201382. https:\/\/doi.org\/10.1007\/s12325-020-01379-x.","journal-title":"Adv Ther"},{"key":"3509_CR159","doi-asserted-by":"publisher","unstructured":"Lu A, Haines B, Zhang W, Zhang M, Whittington DA, Dam Ferdinez ML, et al. 792\u2005TNG917: a potent and orally active inhibitor of euchromatic histone lysine methyltransferases (EHMT1\/2) for the treatment of immune-cold tumors. J Immunother Cancer 2024;12:A897 LP-A897. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0792.","DOI":"10.1136\/jitc-2024-SITC2024.0792"},{"key":"3509_CR160","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz268.073","volume":"30","author":"P Spiliopoulou","year":"2019","unstructured":"Spiliopoulou P, Spear S, Dowson S, Mason S, Blyth K, Fuchter M, et al. Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-\/- murine ovarian cancer model. Ann Oncol. 2019;30: v784. https:\/\/doi.org\/10.1093\/annonc\/mdz268.073.","journal-title":"Ann Oncol"},{"key":"3509_CR161","doi-asserted-by":"publisher","first-page":"B009","DOI":"10.1158\/1538-7445.OVARIAN23-B009","volume":"84","author":"L Nguyen","year":"2024","unstructured":"Nguyen L, Watson ZL, Woodruff ER, Jordan KR, Chuong E, Bitler BG. Abstract B009: Dual PARP and EHMT1\/2 inhibition induces an interferon response and anti-tumor immunity in ovarian cancer. Cancer Res. 2024;84:B009\u2013B009. https:\/\/doi.org\/10.1158\/1538-7445.OVARIAN23-B009.","journal-title":"Cancer Res"},{"key":"3509_CR162","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.23.529773","author":"LL Nguyen","year":"2023","unstructured":"Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, et al. Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models. BioRxiv Prepr Serv Biol. 2023. https:\/\/doi.org\/10.1101\/2023.02.23.529773.","journal-title":"BioRxiv Prepr Serv Biol"},{"key":"3509_CR163","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-23-0613","volume":"23","author":"LL Nguyen","year":"2024","unstructured":"Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, et al. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation. Mol Cancer Ther. 2024;23:1332\u201347. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0613.","journal-title":"Mol Cancer Ther"},{"key":"3509_CR164","doi-asserted-by":"publisher","unstructured":"Nachiyappan A, Gupta N, Taneja R. EHMT1\/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms. FEBS J 2022;289:1329\u201351. https:\/\/doi.org\/10.1111\/febs.16334.","DOI":"10.1111\/febs.16334"},{"key":"3509_CR165","doi-asserted-by":"publisher","unstructured":"Ji Y, Chen W, Wang X. Bromodomain and Extraterminal Domain Protein 2 in Multiple Human Diseases. J Pharmacol Exp Ther 2024;389:277\u201388. https:\/\/doi.org\/10.1124\/jpet.123.002036.","DOI":"10.1124\/jpet.123.002036"},{"key":"3509_CR166","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"Z-Q Wang","year":"2023","unstructured":"Wang Z-Q, Zhang Z-C, Wu Y-Y, Pi Y-N, Lou S-H, Liu T-B, et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy. Signal Transduct Target Ther. 2023;8:420. https:\/\/doi.org\/10.1038\/s41392-023-01647-6.","journal-title":"Signal Transduct Target Ther"},{"key":"3509_CR167","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1038\/s41467-024-46700-2","volume":"15","author":"H Xiang","year":"2024","unstructured":"Xiang H, Xiao Y, Li F, Li C, Liu L, Deng T, et al. Development and validation of an interpretable model integrating multimodal information for improving ovarian cancer diagnosis. Nat Commun. 2024;15:2681. https:\/\/doi.org\/10.1038\/s41467-024-46700-2.","journal-title":"Nat Commun"},{"key":"3509_CR168","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13402-020-00578-6","volume":"44","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Liontos M, Koutsoukos K, Dimopoulos M-A, Zagouri F. Clinical perspectives of BET inhibition in ovarian cancer. Cell Oncol. 2021;44:237\u201349. https:\/\/doi.org\/10.1007\/s13402-020-00578-6.","journal-title":"Cell Oncol"},{"key":"3509_CR169","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1016\/j.celrep.2017.11.095","volume":"21","author":"S Karakashev","year":"2017","unstructured":"Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, et al. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Rep. 2017;21:3398\u2013405. https:\/\/doi.org\/10.1016\/j.celrep.2017.11.095.","journal-title":"Cell Rep"},{"key":"3509_CR170","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00441-018-2906-y","volume":"374","author":"A Liu","year":"2018","unstructured":"Liu A, Fan D, Wang Y. The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity. Cell Tissue Res. 2018;374:577\u201385. https:\/\/doi.org\/10.1007\/s00441-018-2906-y.","journal-title":"Cell Tissue Res"},{"key":"3509_CR171","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00432-021-03885-z","volume":"148","author":"Y Wu","year":"2022","unstructured":"Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, et al. Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. J Cancer Res Clin Oncol. 2022;148:803\u201321. https:\/\/doi.org\/10.1007\/s00432-021-03885-z.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3509_CR172","doi-asserted-by":"publisher","unstructured":"Liu K, Zhou Z, Gao H, Yang F, Qian Y, Jin H, et al. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression. Cell Biol Int 2019;43:642\u201350. https:\/\/doi.org\/10.1002\/cbin.11139.","DOI":"10.1002\/cbin.11139"},{"key":"3509_CR173","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","volume":"16","author":"H Zhu","year":"2016","unstructured":"Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, et al. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Rep. 2016;16:2829\u201337. https:\/\/doi.org\/10.1016\/j.celrep.2016.08.032.","journal-title":"Cell Rep"},{"key":"3509_CR174","doi-asserted-by":"publisher","unstructured":"Xu M, Xu C, Wang R, Tang Q, Zhou Q, Wu W, et al. Treating human cancer by targeting EZH2. Genes Dis 2025;12:101313. https:\/\/doi.org\/10.1016\/j.gendis.2024.101313.","DOI":"10.1016\/j.gendis.2024.101313"},{"key":"3509_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110351","volume":"96","author":"N Li","year":"2022","unstructured":"Li N, Geng F, Liang S-M, Qin X. USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF-\u03baB\/PD-L1 axis to promote the development of cervical cancer. Cell Signal. 2022;96: 110351. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110351.","journal-title":"Cell Signal"},{"key":"3509_CR176","doi-asserted-by":"publisher","unstructured":"Wang Q, Sudan K, Schmoeckel E, Kost BP, Kuhn C, Vattai A, et al. CCL22-Polarized TAMs to M2a Macrophages in Cervical Cancer In Vitro Model. Cells 2022;11. https:\/\/doi.org\/10.3390\/cells11132027.","DOI":"10.3390\/cells11132027"},{"key":"3509_CR177","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.7150\/jca.101881","volume":"15","author":"L Zhang","year":"2024","unstructured":"Zhang L, Tian S, Chang J, Quan S, Yang T, Zhao M, et al. Activation of the CCL22\/CCR4 causing EMT process remodeling under EZH2-mediated epigenetic regulation in cervical carcinoma. J Cancer. 2024;15:6299\u2013314. https:\/\/doi.org\/10.7150\/jca.101881.","journal-title":"J Cancer"},{"key":"3509_CR178","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/1535-7163.MCT-21-0743","volume":"21","author":"P Spiliopoulou","year":"2022","unstructured":"Spiliopoulou P, Spear S, Mirza H, Garner I, McGarry L, Grundland-Freile F, et al. Dual G9A\/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma. Mol Cancer Ther. 2022;21:522\u201334. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0743.","journal-title":"Mol Cancer Ther"},{"key":"3509_CR179","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","volume":"43","author":"P Porazzi","year":"2025","unstructured":"Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al. EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell. 2025;43:537-551.e7. https:\/\/doi.org\/10.1016\/j.ccell.2025.01.013.","journal-title":"Cancer Cell"},{"key":"3509_CR180","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13048-015-0155-1","volume":"8","author":"C Chen","year":"2015","unstructured":"Chen C, Ge J, Lu Q, Ping G, Yang C, Fang X. Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer. J Ovarian Res. 2015;8:28. https:\/\/doi.org\/10.1186\/s13048-015-0155-1.","journal-title":"J Ovarian Res"},{"key":"3509_CR181","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2217\/epi-2017-0022","volume":"9","author":"A Hosseini","year":"2017","unstructured":"Hosseini A, Minucci S. A Comprehensive Review of Lysine-Specific Demethylase 1 and its Roles in Cancer. Epigenomics. 2017;9:1123\u201342. https:\/\/doi.org\/10.2217\/epi-2017-0022.","journal-title":"Epigenomics"},{"key":"3509_CR182","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1007\/s00432-020-03338-z","volume":"146","author":"D Beilner","year":"2020","unstructured":"Beilner D, Kuhn C, Kost BP, J\u00fcckstock J, Mayr D, Schmoeckel E, et al. Lysine-specific histone demethylase 1A (LSD1) in cervical cancer. J Cancer Res Clin Oncol. 2020;146:2843\u201350. https:\/\/doi.org\/10.1007\/s00432-020-03338-z.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3509_CR183","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.3390\/curroncol30020164","volume":"30","author":"DY Lee","year":"2023","unstructured":"Lee DY, Salahuddin T, Iqbal J. Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers. Curr Oncol. 2023;30:2127\u201343. https:\/\/doi.org\/10.3390\/curroncol30020164.","journal-title":"Curr Oncol"},{"key":"3509_CR184","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41388-018-0451-5","volume":"38","author":"Y Qin","year":"2019","unstructured":"Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene. 2019;38:390\u2013405. https:\/\/doi.org\/10.1038\/s41388-018-0451-5.","journal-title":"Oncogene"},{"key":"3509_CR185","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41419-021-03556-4","volume":"12","author":"S Xu","year":"2021","unstructured":"Xu S, Wang X, Yang Y, Li Y, Wu S. LSD1 silencing contributes to enhanced efficacy of anti-CD47\/PD-L1 immunotherapy in cervical cancer. Cell Death Dis. 2021;12:282. https:\/\/doi.org\/10.1038\/s41419-021-03556-4.","journal-title":"Cell Death Dis"},{"key":"3509_CR186","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3892\/ijo.2013.1960","volume":"43","author":"F Meng","year":"2013","unstructured":"Meng F, Sun G, Zhong M, Yu Y, Brewer AM. Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3. Int J Oncol. 2013;43:495\u2013502. https:\/\/doi.org\/10.3892\/ijo.2013.1960.","journal-title":"Int J Oncol"},{"key":"3509_CR187","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235705","volume":"15","author":"R Soldi","year":"2020","unstructured":"Soldi R, Ghosh Halder T, Weston A, Thode T, Drenner K, Lewis R, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch\/Sucrose-NonFermentable (SWI\/SNF) complex mutated ovarian cancer. PLoS ONE. 2020;15: e0235705. https:\/\/doi.org\/10.1371\/journal.pone.0235705.","journal-title":"PLoS ONE"},{"key":"3509_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101307","volume":"12","author":"Y Li","year":"2025","unstructured":"Li Y, Wang B, Zheng Y, Kang H, He A, Zhao L, et al. The multifaceted role of post-translational modifications of LSD1 in cellular processes and disease pathogenesis. Genes Dis. 2025;12: 101307. https:\/\/doi.org\/10.1016\/j.gendis.2024.101307.","journal-title":"Genes Dis"},{"key":"3509_CR189","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1757-2215-6-75","volume":"6","author":"S Konovalov","year":"2013","unstructured":"Konovalov S, Garcia-Bassets I. Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines. J Ovarian Res. 2013;6:75. https:\/\/doi.org\/10.1186\/1757-2215-6-75.","journal-title":"J Ovarian Res"},{"key":"3509_CR190","doi-asserted-by":"publisher","unstructured":"Huang R, Nakamura B, Senguttuvan R, Li Y-J, Martincuks A, Bakkar R, et al. A Critical Role of Intracellular PD-L1 in Promoting Ovarian Cancer Progression. Cells 2025;14. https:\/\/doi.org\/10.3390\/cells14040314.","DOI":"10.3390\/cells14040314"},{"key":"3509_CR191","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-022-00356-0","volume":"11","author":"M Dai","year":"2022","unstructured":"Dai M, Liu M, Yang H, K\u00fc\u00e7\u00fck C, You H. New insights into epigenetic regulation of resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. Exp Hematol Oncol. 2022;11:101. https:\/\/doi.org\/10.1186\/s40164-022-00356-0.","journal-title":"Exp Hematol Oncol"},{"key":"3509_CR192","doi-asserted-by":"publisher","unstructured":"Li X, Li Y, Dong L, Chang Y, Zhang X, Wang C, et al. Decitabine priming increases anti\u2013PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. J Clin Invest 2023;133. https:\/\/doi.org\/10.1172\/JCI165673.","DOI":"10.1172\/JCI165673"},{"key":"3509_CR193","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","volume":"19","author":"Y Lu","year":"2020","unstructured":"Lu Y, Chan Y-T, Tan H-Y, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020;19:79. https:\/\/doi.org\/10.1186\/s12943-020-01197-3.","journal-title":"Mol Cancer"},{"key":"3509_CR194","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1158\/1538-7445.AM2016-4907","volume":"76","author":"ML Stone","year":"2016","unstructured":"Stone ML, Chiappinelli KB, Li H, Murphy L, Topper M, Baylin S, et al. Abstract 4907: Epigenetic treatment of ovarian cancer cells increases immune cell recruitment to the tumor microenvironment: implications for response to immune checkpoint therapy. Cancer Res. 2016;76:4907. https:\/\/doi.org\/10.1158\/1538-7445.AM2016-4907.","journal-title":"Cancer Res"},{"key":"3509_CR195","doi-asserted-by":"publisher","first-page":"7551","DOI":"10.1158\/1538-7445.AM2024-7551","volume":"84","author":"BV Landon","year":"2024","unstructured":"Landon BV, Kaleka G, Balan A, Boland JL, Cherry C, Pereira G, et al. Abstract 7551: Combined epigenetic therapy and immune checkpoint blockade drive reshaping of the tumor microenvironment of platinum resistant ovarian cancer. Cancer Res. 2024;84:7551. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-7551.","journal-title":"Cancer Res"},{"key":"3509_CR196","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s10637-025-01536-5","volume":"43","author":"M Shu","year":"2025","unstructured":"Shu M, Fan Z, Huang B, Wang C. Retrospective analysis of clinical features of pembrolizumab induced psoriasis. Invest New Drugs. 2025;43:582\u20137. https:\/\/doi.org\/10.1007\/s10637-025-01536-5.","journal-title":"Invest New Drugs"},{"key":"3509_CR197","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1158\/0008-5472.CAN-19-1302","volume":"79","author":"T Fukumoto","year":"2019","unstructured":"Fukumoto T, Fatkhutdinov N, Zundell JA, Tcyganov EN, Nacarelli T, Karakashev S, et al. HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. Cancer Res. 2019;79:5482\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1302.","journal-title":"Cancer Res"},{"key":"3509_CR198","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00262-023-03624-y","volume":"73","author":"Y Wen","year":"2024","unstructured":"Wen Y, Ye S, Li Z, Zhang X, Liu C, Wu Y, et al. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy. Cancer Immunol Immunother. 2024;73:7. https:\/\/doi.org\/10.1007\/s00262-023-03624-y.","journal-title":"Cancer Immunol Immunother"},{"key":"3509_CR199","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-017-0358-y","volume":"9","author":"R Mazzone","year":"2017","unstructured":"Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics. 2017;9:59. https:\/\/doi.org\/10.1186\/s13148-017-0358-y.","journal-title":"Clin Epigenetics"},{"key":"3509_CR200","doi-asserted-by":"publisher","unstructured":"Shi W, Han X, Yao J, Yang J, Shi Y. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. Leuk Res 2012;36:749\u201355. https:\/\/doi.org\/10.1016\/j.leukres.2012.01.027.","DOI":"10.1016\/j.leukres.2012.01.027"},{"key":"3509_CR201","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s41375-019-0587-5","volume":"34","author":"P Choudhry","year":"2020","unstructured":"Choudhry P, Mariano MC, Geng H, Martin TG 3rd, Wolf JL, Wong SW, et al. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2020;34:938\u201341. https:\/\/doi.org\/10.1038\/s41375-019-0587-5.","journal-title":"Leukemia"},{"key":"3509_CR202","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","volume":"109","author":"SC Modesitt","year":"2008","unstructured":"Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:182\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2008.01.009.","journal-title":"Gynecol Oncol"},{"key":"3509_CR203","doi-asserted-by":"publisher","unstructured":"El Omari N, Khalid A, Makeen HA, Alhazmi HA, Albratty M, Mohan S, et al. Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat. Heliyon 2024;10. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33052.","DOI":"10.1016\/j.heliyon.2024.e33052"},{"key":"3509_CR204","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3892\/ol.2017.5630","volume":"13","author":"X Ma","year":"2017","unstructured":"Ma X, Wang J, Liu J, Mo Q, Yan X, Ma D, et al. Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells. Oncol Lett. 2017;13:1681\u20137. https:\/\/doi.org\/10.3892\/ol.2017.5630.","journal-title":"Oncol Lett"},{"key":"3509_CR205","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-09-3174","volume":"16","author":"X Ma","year":"2010","unstructured":"Ma X, Liu J, Wu J, Yan X, Wu P, Liu Y, et al. Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant Cells. Clin Cancer Res. 2010;16:5165\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3174.","journal-title":"Clin Cancer Res"},{"key":"3509_CR206","doi-asserted-by":"crossref","unstructured":"Veschi V, Turdo A, Stassi G. Novel insights into cancer stem cells targeting: CAR-T therapy and epigenetic drugs as new pillars in cancer treatment. Front Mol Med 2023;3.","DOI":"10.3389\/fmmed.2023.1120090"},{"key":"3509_CR207","doi-asserted-by":"publisher","first-page":"B021","DOI":"10.1158\/1538-7445.DNAMETHYLATION-B021","volume":"85","author":"EL VanNoy","year":"2025","unstructured":"VanNoy EL, Yi Z, Lee A, El Ghorayeb L, Chiappinelli K, Haydar D. Abstract B021: Epigenetic reprogramming with DNA methylation inhibitors during CAR T cell manufacturing enhances anti-tumor activity, persistence, and cytotoxicity against solid and brain tumors. Cancer Res. 2025;85:B021\u2013B021. https:\/\/doi.org\/10.1158\/1538-7445.DNAMETHYLATION-B021.","journal-title":"Cancer Res"},{"key":"3509_CR208","doi-asserted-by":"crossref","unstructured":"Jo D-H, Kaczmarek S, Khan AUH, Pervin J, Clark DM, Gadde S, et al. Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression. Front Immunol 2025; 16.","DOI":"10.3389\/fimmu.2025.1533044"},{"key":"3509_CR209","doi-asserted-by":"publisher","unstructured":"Osei-Hwedieh D, Fan S, Ferrone S, Wang X, Schwab J, He L, et al. Hdac Inhibitor (Saha) Enhances B7-H3-Specific Car T Cell Cytotoxic Efficacy Against Chondrosarcoma Cells and Prolongs Survival in an Orthotopic Mouse Model. 2024. https:\/\/doi.org\/10.2139\/ssrn.4853690.","DOI":"10.2139\/ssrn.4853690"},{"key":"3509_CR210","doi-asserted-by":"publisher","unstructured":"Harrer DC, Schenkel C, Berking C, Herr W, Abken H, D\u00f6rrie J, et al. Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells. Cancers (Basel) 2022;14. https:\/\/doi.org\/10.3390\/cancers14205033.","DOI":"10.3390\/cancers14205033"},{"key":"3509_CR211","doi-asserted-by":"crossref","unstructured":"Xu Y, Jiang J, Wang Y, Wang W, Li H, Lai W, et al. Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities. Front Immunol 2021;12.","DOI":"10.3389\/fimmu.2021.725330"},{"key":"3509_CR212","doi-asserted-by":"crossref","unstructured":"Wang L, Lin X, Yu L, Sun P. Romidepsin Enhances the Killing Ability of NKG2D-CAR-T Cells through Enhanced Expression of NKG2DL against Ovarian Cancer Cells. CEOG 2022;49:227.","DOI":"10.31083\/j.ceog4910227"},{"key":"3509_CR213","doi-asserted-by":"publisher","unstructured":"Li L-H, Zhang P-R, Cai P-Y, Li Z-C. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway. Biomed Pharmacother 2016;82:161\u20136. https:\/\/doi.org\/10.1016\/j.biopha.2016.04.053.","DOI":"10.1016\/j.biopha.2016.04.053"},{"key":"3509_CR214","doi-asserted-by":"publisher","unstructured":"El Omari N, Lee L-H, Bakrim S, Makeen HA, Alhazmi HA, Mohan S, et al. Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin. Biomed Pharmacother 2023;164:114774. https:\/\/doi.org\/10.1016\/j.biopha.2023.114774.","DOI":"10.1016\/j.biopha.2023.114774"},{"key":"3509_CR215","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12885-022-09197-w","volume":"22","author":"MW Wong-Brown","year":"2022","unstructured":"Wong-Brown MW, van der Westhuizen A, Bowden NA. Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy. BMC Cancer. 2022;22:100. https:\/\/doi.org\/10.1186\/s12885-022-09197-w.","journal-title":"BMC Cancer"},{"key":"3509_CR216","unstructured":"Stone ML. COMBINATION EPIGENETIC THERAPY CAN SENSITIZE OVARIAN CANCER TO IMMUNE CHECKPOINT THERAPY 2017."},{"key":"3509_CR217","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/2326-6066.CIR-15-0073","volume":"3","author":"L Wang","year":"2015","unstructured":"Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, et al. Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. Cancer Immunol Res. 2015;3:1030\u201341. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0073.","journal-title":"Cancer Immunol Res"},{"key":"3509_CR218","doi-asserted-by":"publisher","unstructured":"Alexandraki A, Strati K. Decitabine Treatment Induces a Viral Mimicry Response in Cervical Cancer Cells and Further Sensitizes Cells to Chemotherapy. Int J Mol Sci 2022;23. https:\/\/doi.org\/10.3390\/ijms232214042.","DOI":"10.3390\/ijms232214042"},{"key":"3509_CR219","doi-asserted-by":"publisher","unstructured":"Stiff PJ, Mehrotra S, Potkul RK, Banerjee S, Walker C, Drakes ML. Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice. Cancers (Basel) 2023;15. https:\/\/doi.org\/10.3390\/cancers15184541.","DOI":"10.3390\/cancers15184541"},{"key":"3509_CR220","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.7150\/ijbs.79654","volume":"19","author":"D Yang","year":"2023","unstructured":"Yang D, Huang F-X, Wei W, Li Q-Q, Wu J-W, Huang Y, et al. Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer. Int J Biol Sci. 2023;19:1846\u201360. https:\/\/doi.org\/10.7150\/ijbs.79654.","journal-title":"Int J Biol Sci"},{"key":"3509_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114500","volume":"161","author":"T-H Hsieh","year":"2023","unstructured":"Hsieh T-H, Hsu C-Y, Wu C-W, Wang S-H, Yeh C-H, Cheng K-H, et al. Vorinostat decrease M2 macrophage polarization through ARID1A(6488delG)\/HDAC6\/IL-10 signaling pathway in endometriosis-associated ovarian carcinoma. Biomed Pharmacother. 2023;161: 114500. https:\/\/doi.org\/10.1016\/j.biopha.2023.114500.","journal-title":"Biomed Pharmacother"},{"key":"3509_CR222","doi-asserted-by":"publisher","unstructured":"Xia C, He Z, Cai Y, Liang S. Vorinostat upregulates MICA via the PI3K\/Akt pathway to enhance the ability of natural killer cells to kill tumor cells. Eur J Pharmacol 2020;875:173057. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173057.","DOI":"10.1016\/j.ejphar.2020.173057"},{"key":"3509_CR223","doi-asserted-by":"publisher","first-page":"A32","DOI":"10.1158\/1557-3265.OVCA19-A32","volume":"26","author":"AJ Wilson","year":"2020","unstructured":"Wilson AJ, Dai X, Liu Q, Hiebert S, Crispens M, Khabele D. Abstract A32: Combination panobinostat and olaparib treatment promotes DNA damage and antitumor immunity in ovarian cancer. Clin Cancer Res. 2020;26:A32\u2013A32. https:\/\/doi.org\/10.1158\/1557-3265.OVCA19-A32.","journal-title":"Clin Cancer Res"},{"key":"3509_CR224","doi-asserted-by":"publisher","unstructured":"Jose A, Shenoy P V, Malik Y, Keni SS, Arya N, Kolathur KK. Epigenetic Therapy in Cervical Cancer BT - Epigenetics of Cervical Cancer. In: Kabekkodu SP, Chatterjee A, Chakrabarty S, editors., Singapore: Springer Nature Singapore; 2025, p. 153\u201385. https:\/\/doi.org\/10.1007\/978-981-96-3985-4_11.","DOI":"10.1007\/978-981-96-3985-4_11"},{"key":"3509_CR225","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.ejca.2010.02.047","volume":"46","author":"HJ Mackay","year":"2010","unstructured":"Mackay HJ, Hirte H, Colgan T, Covens A, MacAlpine K, Grenci P, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010;46:1573\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2010.02.047.","journal-title":"Eur J Cancer"},{"key":"3509_CR226","doi-asserted-by":"publisher","unstructured":"Meteran H, Knudsen A\u00d8, J\u00f8rgensen TL, Nielsen D, Herrstedt J. Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer. J Clin Med 2024;13. https:\/\/doi.org\/10.3390\/jcm13030897.","DOI":"10.3390\/jcm13030897"},{"key":"3509_CR227","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/IGC.0b013e31825736fd","volume":"22","author":"DS Dizon","year":"2012","unstructured":"Dizon DS, Damstrup L, Finkler NJ, Lassen U, Celano P, Glasspool R, et al. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2012;22:979\u201386. https:\/\/doi.org\/10.1097\/IGC.0b013e31825736fd.","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"3509_CR228","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/bjc.2014.116","volume":"110","author":"RM Glasspool","year":"2014","unstructured":"Glasspool RM, Brown R, Gore ME, Rustin GJS, McNeish IA, Wilson RH, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2\u2019-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer. 2014;110:1923\u20139. https:\/\/doi.org\/10.1038\/bjc.2014.116.","journal-title":"Br J Cancer"},{"key":"3509_CR229","doi-asserted-by":"crossref","unstructured":"Liang Y, Wang L, Ma P, Ju D, Zhao M, Shi Y. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors. Front Immunol 2023;14.","DOI":"10.3389\/fimmu.2023.1308264"},{"key":"3509_CR230","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12885-025-13851-4","volume":"25","author":"D Marbach","year":"2025","unstructured":"Marbach D, Brouer-Visser J, Brennan L, Wilson S, Davydov II, Staedler N, et al. Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor). BMC Cancer. 2025;25:500. https:\/\/doi.org\/10.1186\/s12885-025-13851-4.","journal-title":"BMC Cancer"},{"key":"3509_CR231","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.annonc.2021.04.013","volume":"32","author":"S Bellone","year":"2021","unstructured":"Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Ann Oncol Off J Eur Soc Med Oncol. 2021;32:1045\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2021.04.013.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03509-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03509-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03509-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:42:23Z","timestamp":1759236143000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03509-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":231,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3509"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03509-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}